Biocon Biologics

Viatris to Sell Entire Equity Stake in Biocon Biologics for $815 Million

Viatris to Sell Entire Equity Stake in Biocon Biologics for $815 Million

10 Dec 2025

1 min read

Health Canada Approves Biocon Biologics’ Yesintek and Yesintek I.V., Biosimilars of Stelara, for Multiple Autoimmune Conditions

Health Canada Approves Biocon Biologics’ Yesintek and Yesintek I.V., Biosimilars of Stelara, for Multiple Autoimmune Conditions

24 Oct 2025

1 min read

Hospitals & Providers

Biocon Biologics Appoints Deepali Naair as Global Head of Brand & Corporate Communications

23 Jul 2025

2 min read

Read More

Voice Of HealthCare

vohnetwork.com